Closed · HT942524GBMRPHDA · CFDA 12.420 · Discretionary
DOD Glioblastoma, Hypothesis Development Award
Federal grant opportunity posted by Dept. of the Army -- USAMRAA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- November 20, 2024
- Close date
- 13
- Expected awards
The verdict
DOD Glioblastoma, Hypothesis Development Award is a closed discretionary listing from Dept. of the Army -- USAMRAA that offered Varies by applicant across 13 expected awards. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 13
- expected awards
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DOD Glioblastoma, Hypothesis Development Award - is cataloged under number HT942524GBMRPHDA and tied to CFDA assistance listing 12.420, posted by Dept. of the Army -- USAMRAA. Grants.gov currently shows the opportunity as closed, first posted on September 16, 2024. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. The agency has projected $4.6 million in total estimated funding for this announcement. It expects to issue 13 awards. If the agency funds the expected 13 awards from the $4.6 million estimated pool, the average award works out to roughly $357,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on November 20, 2024. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
November 20, 2024
Posted
September 16, 2024
Est. Total Funding
$4,640,000
Expected Awards
13
Instrument
Grant
Description
The FY24 GBMRP Hypothesis Development Award supports the exploration of highly innovative, untested, exploratory, high-risk/potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 GBMRP Hypothesis Development Award Focus Areas.This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof-of-principle of an innovative hypothesis, laying the groundwork for future glioblastoma-focused research projects.The GBMRP encourages applications from early-career investigators and applications that include meaningful and productive collaborations between investigators. PIs with little to no previous glioblastoma experience are encouraged to collaborate with experienced glioblastoma researchers and/or clinicians.Key Aspects of the Hypothesis Development Award:Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, proposals should be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.Innovation: It is the responsibility of the Principal Investigators (PIs) to clearly and explicitly articulate how the proposed research project meets the exploratory intent of this mechanism and is innovative in the field of glioblastoma research.Impact: The PI(s) should articulate the short- and long-term impact of the proposed research on both the glioblastoma research field as well as the patient community. The anticipated impact must be significant and move beyond an incremental advancement.Partnering Principal Investigator Option: The FY24 GBMRP Hypothesis Development Award includes an option for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as the Partnering PI. This funding opportunity allows one Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Dept. of the Army -- USAMRAA
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
Department of Defense HIV/AIDS Prevention Program
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |